ReviewImmunologic research2008
Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
Review in Immunologic research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Engineering mRNA CAR-T Cells for Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.Frontiers in immunology · 2021Article
- Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.Trends in cancer · 2019Review
- CAR T cells for infection, autoimmunity and allotransplantation.Nature reviews. Immunology · 2018Review
- Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.JCI insight · 2017Article
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Science translational medicine · 2017Article
- Immunotherapeutic strategies targeting natural killer T cell responses in cancer.Immunogenetics · 2016Review
- Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2016Article
- Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.Cancer immunology, immunotherapy : CII · 2016Review
- Novel immunotherapies for hematologic malignancies.Immunological reviews · 2015Review
- Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells.Immunology · 2014Article
- Th17 cells in cancer: the ultimate identity crisis.Frontiers in immunology · 2014Review
- CD4 T-cell immunotherapy for chronic viral infections and cancer.Immunotherapy · 2013Review
- Dose response kinetics of CD8 lymphocytes from young animals transfused into old animals and challenged with influenza.Immunity & ageing : I & A · 2013Article
- Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2012Review
- The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.Human gene therapy · 2012Article
- Article
- Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.Science translational medicine · 2011Article
- Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.Cancer immunology, immunotherapy : CII · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Many recent advances in basic cell biology and immunology are a harbinger of progress in adoptive cell therapy (ACT) including (1) the finding that host lymphodepletion enhances engraftment and efficacy, (2) the recognition that in vitro T cell functions may not correlate with in vivo efficacy, and (3) the development of advanced ex vivo culture methods to expand lymphocytes to therapeutically effective numbers. In this article, we focus on the development of artificial antigen presenting cells (aAPCs) in our laboratory and their applicability to augment ACT protocols. We also describe how aAPCs can be used to broaden ACT to treat patients with a wide variety of cancers, chronic infectious diseases, and autoimmune manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.